Primary open angle glaucoma (broad sense) or ocular hypertension
Conditions
Interventions
Intervention(s)Omidenepag isopropyl ophthalmic solution is instilled once daily in one or both eyes at night.
Sponsors
Naka Shiratori
Kenji Nakamoto
Santen Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with at least one eye of primary open angle glaucoma (broad sense) or ocular hypertension and no prior therapy within the past 4 weeks 2)Patients who are judged by the investigator or subinvestigator to require treatment for primary open angle glaucoma (broad sense) or ocular hypertension
Exclusion criteria
Exclusion criteria: 1)Patients with aphakia or implanted intraocular lens 2)Patients with any corneal abnormality or other disease that may interfere with accurate IOP measurement with a Goldmann applanation tonometer 3)Patients with a history of refractive corneal surgery 4)Patients with corrected visual acuity of 0.6 or less 5)Patients who may have advanced visual field impairment during the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of Diurnal and Nocturnal mean IOP at Weeks 0 and 4 | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of IOP at each time point at Weeks 0 and 4 Comparison of 24 hour mean IOP at Weeks 0 and 4 Comparison of IOP fluctuation and standard deviations at Weeks 0 and 4 Comparison of IOP elevation between supine and sitting position at Weeks 0 and 4 | — |
Contacts
Public ContactSasaki Miki
Shinanozaka Clinic
Outcome results
None listed